Skip to main content
Protagenic Therapeutics, Inc.\new logo

Protagenic Therapeutics, Inc.\new — Investor Relations & Filings

Ticker · PTIX ISIN · US74365N2027 LEI · 549300KPBYAVJLPDKB70 US Professional, scientific and technical activities
Open in API
Filings indexed 678 across all filing types
Latest filing 2025-01-03 Proxy Solicitation & In…
Country US United States of America
Listing US PTIX

About Protagenic Therapeutics, Inc.\new

https://protagenic.com/

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide-based therapeutics for stress-related disorders. The company's core technology is its TCAP (teneurin C-terminal associated peptide) platform, which utilizes neuropeptides to regulate the brain's stress response at a cellular level. This approach aims to counteract the 'Stress Feedback Loop' implicated in various neuropsychiatric and neurodegenerative conditions. Its lead drug candidate, PT00114, a synthetic TCAP, is being developed as a potential first-in-class treatment for disorders such as anxiety and depression.

Recent filings

Filing Released Lang Actions
Proxy Solicitation & Information Statement 2025
Proxy Solicitation & Information Statement
2025-01-03 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC regarding a Registration Statement on Form S-3. It discusses the withdrawal of a request to accelerate the effective date of the Registration Statement. The content is correspondence related to regulatory filing procedures and does not contain financial data, report content, or detailed disclosures typical of financial reports. The document length is short (1255 characters), and it is a formal communication about a filing status rather than the filing itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence that do not fit other categories.
2024-12-30 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a Form 424B3 prospectus filed pursuant to Rule 424(b)(3) under the Securities Act of 1933. It is a registration statement prospectus for the resale of shares and warrants by selling stockholders, describing the offering, risk factors, company overview, and other related information. This type of document is a capital markets filing related to securities offering and registration, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual prospectus document used for securities offering. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. Confidence is high given the clear identification of the document as a prospectus for a securities offering.
2024-12-27 English
Regulatory Filings 2024
Regulatory Filings
2024-12-27 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting effectiveness of a Registration Statement on Form S-1 filed by Protagenic Therapeutics, Inc. It references the Form S-1 filing and requests the declaration of effectiveness under Rule 461 of the Securities Act of 1933. The document is short (1159 characters) and is a correspondence related to a registration statement filing, not the registration statement itself or a financial report. This type of document is best classified as a Regulatory Filing (RNS) because it is a formal communication with the SEC regarding a regulatory matter and does not contain financial data or report content.
2024-12-23 English
Regulatory Filings 2024
Regulatory Filings
2024-12-20 English

Browse filings by year

30 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.